ALLMedicine™ Advanced Prostate Cancer Center

Jan 14th, 2022 - Individualized supportive care is recommended to manage the debilitating effects of advanced prostate cancer and its treatments. Yet, the implementation of supportive care in practice remains inconsistent. The aim of this study was to synthesize t...

Jan 13th, 2022 - The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (p...

Jan 12th, 2022 - Radical prostatectomy (RP) is a common procedure for localized and locally advanced prostate cancer (PCa). Despite advances in the technique with the introduction of robotic surgery, erectile dysfunction (ED) remains a major drawback. Therefore, a...

Jan 11th, 2022 - The aim of this study is to provide a prospective classification of CD8 high (immunologically "hot") versus CD8 low (immunologically "cold") tumors at the time of treatment, based on the percentage of CD8 cells in a tumor biopsy, and to address th...

Jan 3rd, 2022 - High-risk prostate cancer accounts for approximately 15 percent (%) of newly diagnosed prostate cancers. A systemic therapy that eradicates micrometastatic disease is needed to improve survival in high-risk participants undergoing RP with pLND. It...

Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|radiotherapy,

Sep 23rd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Sep 23rd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

Sep 7th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|diagnostic imaging,radiotherapy,

Aug 12th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

Jan 13th, 2022 - The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (p...

Jan 11th, 2022 - The aim of this study is to provide a prospective classification of CD8 high (immunologically "hot") versus CD8 low (immunologically "cold") tumors at the time of treatment, based on the percentage of CD8 cells in a tumor biopsy, and to address th...

Jan 3rd, 2022 - High-risk prostate cancer accounts for approximately 15 percent (%) of newly diagnosed prostate cancers. A systemic therapy that eradicates micrometastatic disease is needed to improve survival in high-risk participants undergoing RP with pLND. It...

Jan 3rd, 2022 - This is a randomized, double-blind, placebo-controlled, multicenter study of apalutamide plus GnRH agonist compared with GnRH agonist among participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation ther...

Dec 27th, 2021 - Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of ...

Dec 24th, 2021 - Abiraterone acetate with prednisolone should be added to standard treatment for men with high-risk non-metastatic prostate cancer, research suggested. Combination therapy was associated with significantly higher rates of metastasis-free survival c...

Dec 23rd, 2021 - NEW YORK (Reuters Health) - Loss of the NORC2 (nuclear receptor corepressor 2/silencing mediator for retinoid and thyroid hormone receptors) gene could accelerate resistance to androgen deprivation therapy (ADT) in prostate cancer, and novel thera...

Oct 6th, 2021 - Christopher J. Sweeney, MBBS Concomitant therapy with docetaxel and androgen deprivation therapy (ADT) initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men ...

Oct 6th, 2021 - Daniel P. Petrylak, MD Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer (mCRPC), ac...

Oct 6th, 2021 - Grace Lu-Yao, PhD Higher survival rates were observed with radical prostatectomy (RP) and adjuvant radiotherapy (RT) compared with radiotherapy and androgen deprivation therapy (ADT) in men with locally advanced prostate cancer, according to a co...